Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog
Charles Argoff, Fawad A Khan, Steven P Herzog, Ryan M Smith, Seema Soni-Brahmbhatt, Divya Asher, Susanne F Awad, S Wald Grossman, Foram Patel, Dawn C Buse · 2025
Read Real-world effectiveness of eptinezumab in chronic migraine—increase in good days in three subgroups: psychiatric comorbidities, prior subcutaneous anti-calcitonin gene-related peptide therapy, and migraine-associated brain fog by Charles Argoff, Fawad A Khan, Steven P Herzog, Ryan M Smith, Seema Soni-Brahmbhatt, Divya Asher, Susanne F Awad, S Wald Grossman, Foram Patel, Dawn C Buse (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12659521.txt.
Description
Charles Argoff and nine co-authors report real world results for a migraine drug in a study from twenty twenty-five. The drug is eptinezumab, given by infusion for chronic migraine. The report looks at three groups who often get less attention in trials.
One group had mental health conditions as well. One had tried a related injected drug before. One reported brain fog with migraine. All had at least two infusion cycles and rated their good days per month before and after treatment. Good days were defined by each patient. The study asks whether gains in good days hold across all three groups, which would support wider use.
Catalog record
| CREATOR | Charles Argoff, Fawad A Khan, Steven P Herzog, Ryan M Smith, Seema Soni-Brahmbhatt, Divya Asher, Susanne F Awad, S Wald Grossman, Foram Patel, Dawn C Buse |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |